News headlines about GlaxoSmithKline (LON:GSK) have trended somewhat positive on Thursday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news sentiment score of 1.00 on their scale. InfoTrie also assigned news coverage about the company an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the near term.
These are some of the news headlines that may have impacted GlaxoSmithKline’s analysis:
- Barclays Lowers GlaxoSmithKline (GSK) to Equal weight (americanbankingnews.com)
- Stocks to watch: Thomas Cook, GlaxoSmithKline, Campari, Ryanair (ft.com)
- GlaxoSmithKline's credit rating revised to negative at Moody's after Tesaro buyout deal (finance.yahoo.com)
- Somewhat Favorable Press Coverage Extremely Likely to Impact GlaxoSmithKline (GSK) Share Price (americanbankingnews.com)
- GlaxoSmithKline (GSK) Stock Moves -0.7%: What You Should Know (zacks.com)
A number of equities analysts have recently issued reports on GSK shares. Barclays restated an “overweight” rating on shares of GlaxoSmithKline in a research report on Friday, August 10th. Shore Capital restated a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, August 15th. Liberum Capital restated a “buy” rating and set a GBX 1,630 ($21.30) target price on shares of GlaxoSmithKline in a research report on Wednesday, August 15th. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Finally, Jefferies Financial Group set a GBX 1,775 ($23.19) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research report on Thursday, August 16th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,518.84 ($19.85).
The company also recently disclosed a dividend, which will be paid on Thursday, January 10th. Investors of record on Thursday, November 15th will be given a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, November 15th. This represents a yield of 1.26%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: Retained Earnings
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.